HOPE to Reduce Tumour Recurrence After LT In Patients With HCC (POTERE)
Liver Cancer, Tumor Recurrence, Hepatocellular Carcinoma
About this trial
This is an interventional treatment trial for Liver Cancer
Eligibility Criteria
Inclusion Criteria: all patients with HCC medical history or active HCC Donation after circulatory death (DBD) donor with standard or extended criteria Exclusion Criteria: Living transplantation Split Transplantation Combined Transplantation Donation after cardiac death (DCD)Transplantation Re-transplantation Patient whose liver graft will undergo ex-vivo machine perfusion for medical decision, regardless the study
Sites / Locations
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Hypothermic oxygenated Perfusion - HOPE
Static Cold Storage - SCS
Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion, 3000 ml for livers, 1-3 hours. Liver perfusion will be performed through the portal vein at a 5 mmHg pressure. Flow, pressure and temperature will be monitored and registered on REDCap software during organ perfusion. Gas analysis of the effluent perfusate (partial pressure O2 and CO2, pH, lactate and glutamate production) will be accomplished every 15 minutes.
Livers undergoing SCS will be stored in sterile organ bags with Belzer or Celsior solution and cooled in ice until transplant.